Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic).
about
Pro-Inflammatory Markers in Relation to Cardiovascular Disease in HIV Infection. A Systematic ReviewHepatitis B and human immunodeficiency virus co-infectionThe evolving scenario of non-AIDS-defining cancers: challenges and opportunities of careEpidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelinesHIV Infection in the Elderly: Arising ChallengesCause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral TherapyComparison of intima-media thickness and ophthalmic artery resistance index for assessing subclinical atherosclerosis in HIV-1-infected patientsAntiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs studyPegylated IFN-α and ribavirin: emerging data in the treatment of special populations.Impact of Obliterative Portal Venopathy Associated With Human Immunodeficiency VirusImprovement in survival among HIV-infected individuals in the Republic of Korea: need for an early HIV diagnosis.Progressive multifocal leukoencephalopathy in HIV-1 infection.Bacterial pneumonia among HIV-infected patients: decreased risk after tobacco smoking cessation. ANRS CO3 Aquitaine Cohort, 2000-2007.Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era.AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000-2008: hospital-based cohort studiesMortality and causes of death among HIV-infected individuals in the country of Georgia: 1989-2012.Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patientsAt the intersection of HIV/AIDS and cancer: a qualitative needs assessment of community-based HIV/AIDS service organizations.Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden.Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV.Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patientsTh17, gut, and HIV: therapeutic implicationsStrategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1Tobacco smoking in HIV-infected versus general population in france: heterogeneity across the various groups of people living with HIV.Noncommunicable diseases in HIV infection in low- and middle-income countries: gastrointestinal, hepatic, and nutritional aspects.Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort.Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France)Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort.Lung cancer incidence and mortality among HIV-infected and HIV-uninfected injection drug usersRegional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study.FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients.Estimating the extent of underreporting of mortality among HIV-infected individuals in Rio de Janeiro, Brazil.CD4(+) lymphoid tissue-inducer cells promote innate immunity in the gut.HIV and cancer in GermanyCauses of death among people living with AIDS in the pre- and post-HAART Eras in the city of São Paulo, BrazilSmoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America.Persistent immune activation in chronic HIV infection: do any interventions work?HIV-1 infection induces strong production of IP-10 through TLR7/9-dependent pathwaysEffects of Spirulina platensis supplementation on lipid profile in HIV-infected antiretroviral naïve patients in Yaounde-Cameroon: a randomized trial study.An epidemic in evolution: the need for new models of HIV care in the chronic disease era.
P2860
Q26774828-1E48D400-80C3-42C0-AA7C-1813C1A2DFDFQ26822862-DCD4F603-3B6D-49B8-A616-679372736668Q26991549-58C16580-BC98-4933-8523-CBD7C9B28E45Q27023830-23131CC2-A777-43C0-A613-436DCD221421Q28076000-FF57EFAB-E3BF-4B7A-BF34-0AFBD0AFB1A5Q28553516-5B233981-5664-485E-90D9-C4CB8923E592Q30475768-D32BDD8A-F04E-4051-8226-447049CF6248Q30574483-DDD837B2-32C1-48DC-8B39-690BB11545F5Q30733177-1AC6C110-52CD-43B0-8EA7-4453C59BB899Q33430799-563C382A-FAE7-4E03-AC51-A3F11B1D8C4CQ33492609-D3C8B273-C643-4B02-B65C-E8A64767E776Q33506561-0946CF77-8952-4CE8-B969-ACB085B66C6BQ33529099-986C8C70-0D94-432B-A85A-16FABDA25915Q33563357-ECC65A92-2EC4-4D16-BE44-DF8BDBF7A958Q33656320-F5E3086D-4FD4-4422-BABC-EE047DE943E6Q33713778-DD3406DF-D427-4412-B493-61C66C2FF1F6Q33816061-732D5A2B-8163-4202-B5E5-706051160C60Q33835480-F5D24C0A-D54F-43E5-A8AE-AFA8E155BE39Q33883560-4BD2FD35-C5B3-4C6F-8B2D-D55698EFE8FFQ33962303-6B2EC1D9-C034-4AC8-B39C-3A3590EAFCC0Q34022134-F0E768FE-4AD3-4E35-9309-783FCE188CF7Q34050602-A3B4F752-2DEB-49BC-B8B2-ADBBF5D3829CQ34077801-B1FA2C59-F9C8-4529-91C7-CC99608F50E9Q34156186-FF7AE05D-58B6-40A2-92A1-45AACD6D1F89Q34157953-B2FD13B7-B7F9-447C-B023-32B8C88D2835Q34158436-3E0427A1-FE32-4C07-A3ED-9264890FC86FQ34191840-F97A2D54-1B88-4291-8124-8CF3939E8E5BQ34204026-2ED8345D-D4B2-4280-9576-C8E5733B447AQ34283403-F727CB3D-7001-4224-8E7E-F23300704F63Q34388139-BF91DFE0-EA2B-45D9-9F24-D5370CF3C564Q34474404-D6EB942C-9DD2-44EE-9222-26649A1FC41AQ34519466-1F57A090-92B3-4A80-AD61-072402196905Q34562235-68EBC13C-6F9E-4784-B505-135E931D2D8FQ34660212-F70E9D46-A65B-4A31-AA26-209EBFE81141Q34681425-4AF2065B-03D6-4410-830D-A0E78B5731DFQ34823231-1F3A4220-C087-4BCE-A2AB-E221BA9F43F0Q34851102-35C081D0-A1FF-42D2-9F24-80EC86235E66Q34889163-92D80618-1962-4D87-889E-49E5FB51B12DQ34911693-ADD59FEE-D212-4777-B34B-2A44E5F8EB01Q35078744-EB357648-F484-42CC-B4A2-77F082398E89
P2860
Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic).
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Changes in causes of death amo ...... veys (ANRS EN19 and Mortavic).
@ast
Changes in causes of death amo ...... veys (ANRS EN19 and Mortavic).
@en
Changes in causes of death amo ...... rtalité 2000 and 2005" surveys
@nl
type
label
Changes in causes of death amo ...... veys (ANRS EN19 and Mortavic).
@ast
Changes in causes of death amo ...... veys (ANRS EN19 and Mortavic).
@en
Changes in causes of death amo ...... rtalité 2000 and 2005" surveys
@nl
prefLabel
Changes in causes of death amo ...... veys (ANRS EN19 and Mortavic).
@ast
Changes in causes of death amo ...... veys (ANRS EN19 and Mortavic).
@en
Changes in causes of death amo ...... rtalité 2000 and 2005" surveys
@nl
P2093
P50
P1476
Changes in causes of death amo ...... veys (ANRS EN19 and Mortavic).
@en
P2093
ANRS EN19 Mortalité Study Group and Mortavic1
Caroline Semaille
Charlotte Lewden
Christine Burty
Dominique Salmon
Eric Jougla
Eric Rosenthal
Fabrice Bonnet
Philippe Morlat
Thierry May
P304
P356
10.1097/QAI.0B013E31817EFB54
P407
P577
2008-08-01T00:00:00Z